Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

Jefferies analyst Akash Tewari maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on February 3 and set a price target of ...

Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is headquartered in Indianapolis, Indiana. Read More on LLY: Eli Lilly ...

Eli Lilly's Q4 FY24 guidance adjustment is due ... list pricing illustrates how pricing reforms could impact the company's products. Inflation Reduction Act Competition in the GLP-1 market ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Eli Lilly and Company discovers, develops ... It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.